Background: Treatments designed to correct cystic fibrosis transmembrane conductance regulator (CFTR) defects must first be evaluated in preclinical experiments in the mouse model of cystic fibrosis (CF). Mice nasal mucosa mimics the bioelectric defect seen in humans. The use of nasal potential difference (VTE) to assess ionic transport is a powerful test evaluating the restoration of CFTR function. Nasal VTE in CF mice must be well characterized for correct interpretation. Methods: We performed VTE measurements in large-scale studies of two mouse models of CF—B6;129 cftr knockout and FVB F508del-CFTR—and their respective wild-type (WT) littermates. We assessed the repeatability of the test for cftr knockout mice and defined cutoff points d...
<div><p>Animal models for cystic fibrosis (CF) have contributed significantly to our understanding o...
Cystic Fibrosis, an autosomal recessive disease frequently seen in the Caucasian population, is char...
Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conduct...
BACKGROUND: Treatments designed to correct cystic fibrosis transmembrane conductance regulator (CFTR...
Cystic Fibrosis (CF) is caused by a defect in the CF transmembrane conductance regulator (CFTR) gene...
The nasal potential difference test has been used for almost three decades to assist in the diagnosi...
Background: Nasal potential difference (NPD) test has long been used to assist in the diagnosis of C...
an approved drug for treating Gaucher disease, was reported to be able to correct the defective traf...
RATIONALE: N-butyldeoxynojyrimicin (NB-DNJ, miglustat, Zavesca) an approved drug for treating Gauche...
International audienceMutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene (CFT...
Cystic Fibrosis (CF) is the most common severe genetic disease among the Caucasian population. It is...
Objectives: To characterize transepithelial nasal potential difference in β- ENaC overexpressing mou...
Most cystic fibrosis (CF) patients produce a mutant form (delta F508) of the cystic fibrosis transme...
<div><p>Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane...
Animal models for cystic fibrosis (CF) have contributed significantly to our understanding of diseas...
<div><p>Animal models for cystic fibrosis (CF) have contributed significantly to our understanding o...
Cystic Fibrosis, an autosomal recessive disease frequently seen in the Caucasian population, is char...
Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conduct...
BACKGROUND: Treatments designed to correct cystic fibrosis transmembrane conductance regulator (CFTR...
Cystic Fibrosis (CF) is caused by a defect in the CF transmembrane conductance regulator (CFTR) gene...
The nasal potential difference test has been used for almost three decades to assist in the diagnosi...
Background: Nasal potential difference (NPD) test has long been used to assist in the diagnosis of C...
an approved drug for treating Gaucher disease, was reported to be able to correct the defective traf...
RATIONALE: N-butyldeoxynojyrimicin (NB-DNJ, miglustat, Zavesca) an approved drug for treating Gauche...
International audienceMutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene (CFT...
Cystic Fibrosis (CF) is the most common severe genetic disease among the Caucasian population. It is...
Objectives: To characterize transepithelial nasal potential difference in β- ENaC overexpressing mou...
Most cystic fibrosis (CF) patients produce a mutant form (delta F508) of the cystic fibrosis transme...
<div><p>Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane...
Animal models for cystic fibrosis (CF) have contributed significantly to our understanding of diseas...
<div><p>Animal models for cystic fibrosis (CF) have contributed significantly to our understanding o...
Cystic Fibrosis, an autosomal recessive disease frequently seen in the Caucasian population, is char...
Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conduct...